Chairman's Address to Shareholders
Released
Released
Announcement PDF
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
25 May 2023
AGM – Transcript of Chairman’s Address
Dear Shareholders,
As we noted in our Annual Report, 2022 was a momentous year. We showed that our imaging
agent technology was safe and well tolerated, not just in healthy volunteers like most Phase 1
studies, but in actual breast cancer patients. Additionally, we ended the year being the first
company ever to conduct a clinical study and present clinical data for the targeted imaging of
cancer using magnetic nanoparticles. We have shown that our nanoparticle imaging technology
could be used to non-invasively detect cancer, not just in laboratory animals but actual human
patients. From both a scientific perspective and a business perspective, this is a major success.
Yes, recruitment has been challenging, but WE DID IT. We have positive data from patients with
metastatic breast cancer. If you compare our achievement to the number of drugs or devices that
fail in early-stage clinical studies, we’ve delivered a significant milestone.
And now we have carried the momentum from 2022 into 2023. In early February we reported that
a review of our Phase 1 data by an independent group of radiologists corroborated two key
findings:
1. that our MagSense imaging agent was detectable in the patient’s lymph nodes; and
2. that using Magnetic Resonance Imaging, the radiologist observed a differentiated image
between normal lymph nodes and nodes that could contain cancer cells.
This independent corroboration of the study imaging results has enabled us to shift the strategy
for our nanoparticle pipeline towards using MRI for the molecular imaging of cancer. The MRI
approach opens the door to a faster and more economical path to commercialisation than
developing and introducing a new type of detection technology. We anticipate that by leveraging
existing MRI we can develop a more proximate revenue pathway for our imaging agents, initially
targeting HER2 breast cancer, and in the future other cancers such as ovarian and prostate cancer.
This year we will continue to advance our pipeline for molecular MRI as we believe this strategy to
be more attractive for strategic partners and more likely to achieve commercial success sooner for
us.
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com
By prioritizing molecular MRI for our nanoparticle technology, our development path has become
clearer and less complicated. And as a result, we were able to initiate communication with the U.S.
FDA to expand our MagSense® HER2 development for breast cancer detection to a Phase 2 study.
Over the next several months we will be completing additional work and preparing for our
submission of an Investigational New Drug (IND) application to the FDA. Receiving clearance of
an IND is a major technical and regulatory milestone in-and-of itself. Most biotech and pharma
companies see the IND as a significant milestone and value inflection point because of the rigor
and supporting evidence needed to gain FDA’s IND clearance.
Since the beginning of this year, we have continued to enrol into the Phase 1 study and are
expecting soon to complete the second cohort of patients. Given the satisfactory evidence
supporting our primary and secondary endpoints and the recent guidance we have received from
the FDA regarding our plans for the Phase 2 study, we believe we can now begin winding down
the Phase 1 study. I acknowledge that it has taken longer to complete than we thought when we
initiated the study, but the positive outcome of this study marks an important accomplishment for
the company.
In summary, in the last two years we have taken our lead product for breast cancer from benchtop
to a positive outcome in a Phase 1 study. Additionally, we have demonstrated that our nanoparticle
technology is, indeed, a platform for targeted molecular imaging having reported preclinical results
for both prostate cancer and ovarian cancer. Pursuing use of our nanoparticle technology with
conventional MRI will reduce the risk, time and cost of our development path. Additionally, it is
more likely to be an attractive commercial prospect for partners, while still preserving the
opportunity for our proprietary magnetic relaxometry technology to play a role in the future.
With the success we are claiming from our Phase 1 study you may be asking why we need to do
a Phase 2 study or what we expect to gain from it. Firstly, I’d like to remind everyone that the
Phase 1 study was always intended as a proof-of-principle for our nanoparticle technology. Since
our nanoparticles had never been tested in human subject before, it was important that we start
with a limited study before committing to larger numbers of patients. And because no one had
ever tested a targeted imaging agent before, and because we weren’t only testing for safety in
healthy volunteers, in our Phase 1 study we had to take our best guess as to what dose to give
patients and at what time point or points we should be imaging. But by including this as part of the
Phase 1, we now have data to inform the next study. As challenging as it has been these first
patients have been instrumental in establishing the baseline for our future work.
In the Phase 2 study we will start with dose ranging, that is, reducing the dose to see how low we
can go while still achieving detectability. Think of this for a moment. This is good all around.
Patient safety is likely to be better with smaller doses and our gross margins can be higher if we
use a smaller amount of imaging agent to achieve the same diagnostic outcome and price.
Additionally, in the first patients of the Phase 2 study we will be looking to optimize the timing of
when the MRI is taken. Once we have established a more optimal dose and timing, we will expand
the study to a larger group of patients.
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com
Given the slow recruitment into the Phase 1 Study here in Australia, what does that mean for
recruiting a larger number of patients for Phase 2? There are three things working in our favour.
Firstly, in many other countries, including the US, population size means there are just a lot more
patients. Secondly, we can have many more sites recruiting in parallel. And thirdly, since we were
only going to test a limited number in the Phase 1 study, we had to focus on patients suspected of
nodal disease. This has meant that more than half of the HER2 breast cancer patients have not
been eligible. In the Phase 2 study we will recruit from all HER2 positive patients.
In 2022 we made real progress in our mission to improve cancer detection and have charted a
clear path with and updated strategy that will move us towards our goal of commercializing our
nanoparticle platform. I understand that for our shareholders it can be hard to be enthusiastic about
these “wins” or accomplishments and the prospects for the future when the share price is suffering;
and the fact that over the last year approximately 80% of the ASX bio-techs have been trading
down is no real consolation.
Recently, I heard of an analyst who has been watching IBX. He told a colleague that he liked the
IBX story but that we still had some wood to chop. I liked this analogy because it implies if we do
the work, we have the makings of a roaring fire. In my opinion, and that of our Board, the IBX share
price does not reflect the value we have created and are creating.
Over this past year we have seen a number of the large pharma companies including Novartis,
Merck, and Bayer being interested in the diagnostic imaging space and licensing and partnering
with companies developing targeted radiotracers and radiopharmaceuticals. We believe this
bodes well for our strategic plan of partnering, and towards that end we recently opened a secure
data room where we can share confidential information with prospective strategic partners. With
our MagSense® imaging agent for breast cancer now laying the groundwork for our technology to
be first in class for molecular imaging by MRI, we believe we can help to change the way we see
cancer.
To realize this potential, we have to continue to push forward. Every additional step through the
clinical and regulatory process adds value and takes risks off the table; but it also requires having
access to working capital. We know that markets and economic conditions in Australia, and indeed
globally, have been difficult and may continue to be so. So I’d particularly like to thank the
shareholders that participated in the recent entitlement offer. Your support for the company is
greatly appreciated. But it is exactly those market conditions that also highlight why having a
financing instrument like we have put in place with Mercer Street Capital is so important for a
company like Imagion. We don't intend to solely rely on this instrument to fund the company, but
having it means we have access to working capital without having to worry about timing of market
conditions. With $3.5M of funds expected to come in this quarter from our ATO tax credit, we aim
to use the Mercer funding judiciously to keep our drive towards the IND on track.
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com
Now before closing my remarks and moving on to the formal meeting, I’d like to speak briefly to
the recent announcement of my plans to retire from the role of CEO. While I am not the founder
of the company, I have fully vested myself in the vision and mission of Imagion and believe strongly
in what we are trying to accomplish and the value it will create. So I can assure our shareholders
that my plans to retire from the role of CEO does not mean I will be riding off into the sunset. The
Board and I are fully committed to the principles of good governance and plan for me to remain as
Chairman of the Board to keep the momentum going and ensure we preserve the knowledge and
history gained over the years of my leadership so that we are successful in the next phase of our
journey.
In closing, I’d like to thank all the Imagion stakeholders for their support – shareholders, customers,
collaborators, advisors, employees, Directors, and particularly those breast cancer patients that
have, despite their medical diagnosis, participated in our study and the physicians and study teams
who executed on the protocol. We are looking forward to our future and to achieving our goal of
changing the way we see cancer to positively impact patient outcomes.
-ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular
imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect
cancer and other diseases earlier and with higher specificity than is currently possible.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Board of Directors of Imagion Biosystems Limited
U.S. Media Contact:
Casie Ost
Casie.ost@imagionbio.com
+1-619-693-4428
Australian Media & Investor Relations:
Hannah Howlett, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61 450 648 064
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com
Share your feedback
Discover